ERBB2 and breast cancer: Aspirin pre‐treatment delays primary tumour growth and metastatic dissemination of Her2+MDA‐MB‐231/LM2‐4/H2N tumours but does not increase overall survival compared to SOC in the trastuzumab‐resistant HCC1954 Her2+BC model